Herpes zoster in multiple myeloma patients during bortezomib treatment
https://doi.org/10.17650/1818-8346-2011-6-3-35-38
Abstract
Recent advances in multiple myeloma (MM) treatment associated with new drug use including bortezomib. Experiences in wide ambul atory drug use confirm therapy success for this serious disease, but at the same time reveals the most common side effects. One of th e most significant is the reactivation of Herpes zoster , which leads to decrease MM therapy results because of inability to perform standard therapy in these patients. Literature data and own experiences about reactivation of Herpes zoster during bortezomib therapy as monothe rapy and in combination, which varies from 7 to 34% according to different authors and 25% of own experiences, is presented. Treatment and preventive schedule of this complication are shown.
About the Authors
I. N. Nazarova
Krasnogorsk Hospital № 1
Russian Federation
Russian Federation
M. N. Protasova
Krasnogorsk Hospital №3
Russian Federation
Russian Federation
N. A. Nikishina
Krasnogorsk Hospital №3
Russian Federation
Russian Federation
References
1. Внутренние болезни. Под ред. Т.Р. Харрисона, т. 4. М.: «Медицина», 1994.
2. Поспелова Т.И., Скворцова Н.В., Ковынев И.Б. и др. Эффективность бортезомиба в терапии рецидивов и рефрактерных форм множественной миеломы. Гематол и трансфузиол 2009;54(1):43.
3. Basler M., Lauer C., Beck U. et al. The proteasome ingibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009;183:6145–50.
4. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I. et al. Bortezomib induces selective depletion of alloreactive T lympho cytes and decreases the production of Th1 cytokines. Blood 2006;107:3575–83.
5. Chanan-Khan A., Sonneveld P., Schuster M.W. et al. Analysis of Herpes Zoster events among bortezomib-treated patients in phase III APEX study. J Clin Oncol 2008;26:4784–90.
6. Dasanu C.A., Alexandrescu D.T. Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma? J Clin Oncol 2009;27(13):2293–4.
7. Kim S.J., Kim K., Kim B.S. et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymph Myel 2008;8(4):237–40.
8. Maseda D., Meister S., Neubert K. et al. Proteasome ingibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 2008;15:600–12.
9. Mateos M.V., Hernandes J.M., Hernandes M.T. et al. Bortesomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase ½ study. Blood 2006;108:2165–72.
10. Morison W.L. Letter: Herpes simplex and herpes zoster in neoplasia. Lancet 1974;1:1293.
11. Palumbo A., Ambrosini M.T., Benevolo G. et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 2007;109(7):2767–72.
12. Pour L., Adam Z., Buresova L. et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymph Myel 2009;9(2):151–3.
13. Schutt P., Brandhorst D., Stellberg W. et al. Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections. Leuk Lympoma 2006;47:1570–82.
14. Vickrey E., Allen S., Mehta J. et al. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009; 115:229–32.
Review
For citations:
Nazarova I.N., Protasova M.N., Nikishina N.A. Herpes zoster in multiple myeloma patients during bortezomib treatment. Oncohematology. 2011;6(3):35-38. (In Russ.) https://doi.org/10.17650/1818-8346-2011-6-3-35-38
Views:
10039
Email this article 